DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2032)

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Landscape & Forecast | Disease Landscape & Forecast

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year forecast period. One of these novel therapies is Yescarta, the first chimeric antigen receptor (CAR) T-cell therapy; it is approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and represents a significant milestone in NHL drug development. Offsetting this market growth will be the biosimilar erosion expected for rituximab, the patient- and market-share leader in 2017 in the NHL space, and the generic erosion of Revlimid (and, to a lesser extent, bendamustine). Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.

Questions Answered:

  • Kinase inhibitors have changed the NHL treatment algorithm since their recent approval. Which kinase inhibitors are most promising in NHL, and what patient populations will they target? What will be their impact on the NHL market?
  • Rituxan/MabThera is widely used in all NHL drug-treated populations and garners significant sales. How will market share for rituximab change over our ten-year forecast period as a result of biosimilars? Will Gazyva/Gazyvaro achieve the same status as Rituxan/MabThera within the NHL space and thus minimize the impact of biosimilar erosion of branded rituximab?
  • The NHL therapy market will experience robust growth through 2027. What factors are driving this growth? Which drug class will dominate the treatment of NHL? What new classes of agents will emerge over the ten-year forecast period, and what will be their market impact?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 20 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.

Epidemiology: Diagnosed incidence of follicular lymphoma (FL) (including transformed FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), DLBCL, and mantle cell lymphoma (MCL).

Population segments in market forecast: First line, second line, and third/fourth line for FL, CLL/SLL, DLBCL, and MCL.

Emerging therapies: Phase I and II: 45 drugs; Phase III: 10 drugs; registered: 5 drugs.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • May 2019
      • February 2019
      • December 2018
      • October 2018
      • September 2018
      • June 2018
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for NHL?
        • What Factors Are Constraining the Market for NHL?
      • Segment-Specific Trends
        • First-Line CLL/SLL
        • Relapsed/Refractory CLL/SLL
        • First-Line DLBCL
        • Relapsed/Refractory DLBCL
        • First-Line FL
        • Relapsed/Refractory FL
        • First-Line MCL
        • Relapsed/Refractory MCL
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
      • Staging and Classification
        • Staging of NHL
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • De Novo DLBCL Incident Cases by Molecular Subtype
        • Transformed Incident Cases from FL to DLBCL
        • Transformed Incident Cases from CLL to DLBCL
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Monoclonal Antibodies
        • Apoptosis-Inducing Agents
        • Immunomodulatory Agents
        • Proteasome Inhibitors
        • mTOR Inhibitors
        • Kinase Inhibitors
        • Chemotherapies
        • CAR T-Cell Therapies
        • Immune Checkpoint Inhibitors
      • Medical Practice
        • Drug-Treatable Population
        • Country-Specific Treatment
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in NHL
    • Emerging Therapies Overview
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for NHL
        • Kinase Inhibitors
        • Monoclonal Antibodies/Antibody-Drug Conjugates
        • CAR T-Cell Therapies
        • Immune Checkpoint Inhibitors
        • Selective Inhibitors of Nuclear Export
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for NHL
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Bibliography

Already a Client? Log in to access this report.

  • Pub Date: May 2019
  • Author(s): Sorcha Cassidy M.Res., Ph.D; Nicole Zhang, MPH
  • Sorcha Cassidy , is an Associate Director in the Oncology team at Decision Resources ; Dr. Cassidy manages a team of analysts who conduct extensive primary and secondary market research on several Oncology indications across the major pharmaceutical markets. She also provides sales and client support across all oncology products. She has in-depth expertise in competitive intelligence, secondary and primary market research, and delivering strategic insights that address key client business questions. Dr. Cassidy holds an and in Immunology from Imperial College London where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIR) on natural killer (NK) cells in various diseases and published several peer-reviewed papers. Prior to joining the company, Dr. Cassidy previously worked as a Market Research Manager in Janssen UK and has extensive experience working across multiple Oncology indications at GlobalData and FirstWord Pharma.

  • Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders. She holds an from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.

Purchase Report

Recent reports:
You may also be interested in: